Eisai Co., Ltd. and Sysmex Corporation, a pharmaceutical company based in Kobe, Japan have entered into a comprehensive non-exclusive collaboration agreement for diagnostics in the field of dementia.

While diagnosis of Alzheimer’s disease is sometimes made by using tests such as brain imaging examinations and cerebrospinal fluid examinations, various issues, such as the insufficient number of facilities for examinations, the high cost, and the invasiveness of the testing remain to be addressed. As such, there is a need for the development of technologies that will enable diagnoses to be made less invasive and costly.

Sysmex specializes in clinical diagnostics and technologies for detection of genetic, protein and cellular biomarkers in blood samples.

In collaboration with Eisai, Sysmex will lead the development of diagnostics, and will exclusively market these diagnostics worldwide after receiving regulatory approval. Eisai will receive payments for meeting development milestones, launching products, as well as royalties on sales, and Eisai will utilize these diagnostics for drug discovery and development in the field of dementia.

Source: Eisai